Medication info
Hannn Memantine Orally Disintegrating Tablets 5 mg (Memantine Hydrochloride)

Hannn Memantine Orally Disintegrating Tablets 5 mg (Memantine Hydrochloride)

Prescription medicationOrally disintegrating TabletOral
Ingredient · strength
Memantine Hydrochloride›5mg / 1 tablet
Manufacturer / importer
Hann Pharmaceutical Co., Ltd.
Appearance
White round orally disintegrating tablet
Packaging
Domestic - 90 tablets/box [10 tablets/PTP×9], Export - 30 tablets/box [10 tablets/PTP×3]
Approval status
Active

MFDS item code 201706583 · Approved 2017.08.14 · Insurance code 657203180

Summary

Main use
Treatment of moderate to severe Alzheimer’s disease
Who takes it
Adults
Adult dose
Administer this medicine orally once daily at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. This medicine is an orally disintegrating tablet. Place it on the tongue and allow it to dissolve; take it without water. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows until the maintenance dose is reached. Week 1 (Day 1~7) Administer 5mg once daily for 7 days. Week 2 (Day 8~14) Administer 10mg once daily for 7 days. Week 3 (Day 15~21) Administer 15mg once daily for 7 days. Starting in Week 4 Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults: Based on clinical data, the recommended dose for older patients aged 65 years or older is 20mg once daily. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If the dose is well tolerated after at least 7 days of treatment, it may be increased to 20mg once daily according to the standard dose-escalation regimen. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine to them.

Ingredients

Manufacturer
Hann Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer’s disease

View approved original text

This medication is used to treat the symptoms of Alzheimer's disease ranging from moderate to severe.

How to take

Adult dose

Administer this medicine orally once daily at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. This medicine is an orally disintegrating tablet. Place it on the tongue and allow it to dissolve; take it without water. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows until the maintenance dose is reached. Week 1 (Day 1~7) Administer 5mg once daily for 7 days. Week 2 (Day 8~14) Administer 10mg once daily for 7 days. Week 3 (Day 15~21) Administer 15mg once daily for 7 days. Starting in Week 4 Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults: Based on clinical data, the recommended dose for older patients aged 65 years or older is 20mg once daily. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If the dose is well tolerated after at least 7 days of treatment, it may be increased to 20mg once daily according to the standard dose-escalation regimen. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine to them.

Precautions

This medication contains the artificial sweetener aspartame, which breaks down into phenylalanine in the body. Therefore, patients with a genetic disorder called phenylketonuria should not take this medication. Care should be taken not to exceed the daily maximum allowable dose of aspartame, and it is safe for adults to consume less than 2.4 grams per day. Patients who are allergic to any component of this medication or have severe liver or kidney dysfunction should not use it. Those with epilepsy or a history of seizures should take this medication with caution as the risk of side effects may increase when taken with certain central nervous system drugs. Patients with changes in urine acidity or recent heart conditions should also take caution. Side effects such as dizziness, headaches, constipation, drowsiness, and hypertension may occur while taking this medication; if symptoms are severe, consult a physician. There may be interactions with other medications, so special caution is needed when taken with NMDA antagonists, antipsychotic drugs, skeletal muscle relaxants, anticoagulants, etc. Pregnant women or those who may become pregnant should consult a physician before taking this medication, and it is advisable to discontinue breastfeeding if nursing. The safety and efficacy of this medication have not been confirmed for children and adolescents under the age of 18, so it is best not to use it. In case of overdose, symptoms such as confusion, drowsiness, hallucinations, and seizures may occur, requiring immediate medical attention. This medication may affect the patient's mental state or reaction time, so caution is necessary when driving or operating machinery. Lastly, keep this medication out of the reach of children and do not transfer it to other containers.

Side effects

Dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. By storing it this way, the efficacy and safety of the medication can be well maintained.

Appearance and packaging

Appearance

White round orally disintegrating tablet

Package unit

Domestic - 90 tablets/box [10 tablets/PTP×9], Export - 30 tablets/box [10 tablets/PTP×3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.